Overview Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia Status: Completed Trial end date: 2007-11-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine how effective, and to what extent, Iressa is in the treatment of acute myelogenous leukemia. Phase: Phase 2 Details Lead Sponsor: Dana-Farber Cancer InstituteCollaborators: Boston Children's HospitalBoston Children’s HospitalBrigham and Women's HospitalTreatments: Gefitinib